Marinomed Biotech (MARI) investor relations material

Leadership and Ownership

• Leadership team includes experienced biotech entrepreneurs and industry veterans, with significant management and founder ownership and a large free float of 73.5%.

• Long-term shareholders from the Middle East have supported the company since 2006.

Strategic Assets and Partnering

• Budesolv and Tacrosolv, two late-stage assets, have completed successful clinical trials and are in advanced partnering discussions with Big Pharma, targeting multi-billion dollar allergy and ophthalmology markets.

• Budesolv is at term sheet stage, Tacrosolv at LOI stage, with Budesolv registration ongoing in Switzerland and launches planned post-approval.

• Tacrosolv development continues through strategic partnerships, with phase 3 trials and compounding business expansion targeted for 2027-2028.

• Recent capital increase strengthens negotiation position and supports milestone achievement.

• All non-external funded projects are on hold to focus resources on top commercialization opportunities.

Technology and Business Model

• Proprietary Marinosolv technology enables solubilization of insoluble drugs, with patents and clinical validation.

• Business model includes in-house projects, client-sponsored Solv4U services, and new component supply for compounding pharmacies.

• Revenue streams include upfront payments, milestones, royalties, service fees, and supply to compounding pharmacies.

• Strategic focus on partnering, cost efficiency, and ramping up compounding business to optimize cash flow and profitability.